Treatment speed crucial to 1-year stroke survival
Article written by Bruce Sylvester
Article written by Bruce Sylvester
Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.
Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.
Article written by Bruce Sylvester Investigators have validated a first-line combination therapy that significantly improves survival in patients with hepatocellular carcinoma, the most common liver cancer.
Article written by Bruce Sylvester
The FDA approved Ilaris (canakinumab) injection for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD). Ilaris was previously approved for Systemic Juvenile Idiopathic Arthritis (SJIA)… read more.
Ultragenyx Pharmaceutical Inc.and Kyowa Kirin Co., Ltd. announced that the FDA has approved Crysvita (burosumab) for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia… read more.
Interview and article by Christine Clark. Compared with ibuprofen, indomethacin has additional beneficial actions, argues Dr Rajan Ravichandran Commenting on the LIBERATE* study (NCT04334629) that is now in… read more.
Interview and article by Christine Clark. Dr Rajan Ravichandran’s experience of using indomethacin to control cytokine release syndrome led him to realise that it could also be useful… read more.
Interview and article by Christine Clark. Indomethacin has both anti-inflammatory and anti-viral properties and it could help to hasten recovery from covid-19 infection Indomethacin, if given early to… read more.
Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, continuous glucose monitoring (CGM) technology, is associated with significant reduction in hemoglobin A1c (HbA1c) levels for… read more.
Sun Pharmaceutical Industries announced further evidence of the long-term use and cost-effectiveness of Ilumya (tildrakizumab-asmn) in moderate-to-severe plaque psoriasis. Long-term analyses of the phase III reSURFACE 1 and… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.